NDA 219488 · Mirum
Ctexli
Chenodiol · Oral · Bile Acid
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 21, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
3 Phase 3, 1 recruiting
FAERS reports
32
17 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2025.
CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. CTEXLI is a bile acid indicated for treatment of cerebrotendinous xanthomatosis (CTX) in adults. ( 1 )
Mechanism: Endogenous chenodiol (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the endogenous bile acid chenodeoxycholic acid in patients with CTX. Increased chenodiol levels in the enterohepatic bile acid pool restore the activation of farnesoid X receptor (FXR) and downregulate CYP7A1 leading to suppression and reduction of atypical bile acids and bile alcohols...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 21, 2025 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanLabelLetterReview
1 products under this application
- CTEXLI · CHENODIOL 250MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Chenodiol" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).Pivotal-lookingRecruiting
Myungmoon Pharma. Co. Ltd.Industry
NCT07005752 · 484 participants (planned) · Start Jul 28, 2025 · Primary completion Nov 10, 2027
Drug: CnU cap. 250mg & Ursa placebo tab. 200mg; Ursa tab. 200mg & CnU placebo cap. 250mg · For: Cholesterol Cholelithiasis
Sites: Ansan, South Korea; Bucheon-si, South Korea; Suwon, South Korea · 13 sites in all
- Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisPivotal-lookingCompleted
Intercept PharmaceuticalsIndustry
NCT01473524 · 217 participants · Start Jan 2012 · Primary completion Dec 2013
Drug: Obeticholic Acid (OCA); Placebo · For: Primary Biliary Cirrhosis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 59 sites in all
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)Pivotal-lookingTerminated
Intercept PharmaceuticalsIndustry
NCT00550862 · 165 participants · Start Oct 2007 · Primary completion Aug 2009
Drug: INT-747; Ursodeoxycholic Acid (URSO) and 1 more · For: Liver Cirrhosis, Biliary
Sites: Gainesville, Florida; Miami, Florida; Boston, Massachusetts · 32 sites in all
Lars Kristian MunckAcademic, hospital or other
NCT03059537 · 71 participants · Start Mar 13, 2017 · Primary completion Nov 27, 2017
Drug: Oral chenodeoxycholic acid stimulation · For: Bile Acid Malabsorption
Sites: Aalborg, Denmark; Aarhus, Denmark; Holbæk, Denmark · 5 sites in all
Intercept PharmaceuticalsIndustry
NCT00570765 · 60 participants · Start Jan 17, 2008 · Primary completion Sep 21, 2010
Drug: Placebo; Obeticholic Acid (OCA) · For: Liver Cirrhosis, Biliary
Sites: Detroit, Michigan; Houston, Texas; Richmond, Virginia · 21 sites in all
Capricor Inc.Industry
NCT04623671 · 55 participants · Start Nov 15, 2020 · Primary completion Feb 4, 2022
Drug: CAP-1002; Placebo · For: Covid19
Sites: Los Angeles, California; Sacramento, California; Detroit, Michigan · 4 sites in all
Mayo ClinicAcademic, hospital or other
NCT00912301 · 36 participants · Start Apr 2009 · Primary completion Nov 2009
Drug: Sodium chenodeoxycholate (NaCDC) · For: Constipation-predominant Irritable Bowel Syndrome
Sites: Rochester, Minnesota
Imperial College Healthcare NHS TrustAcademic, hospital or other
NCT01585025 · 35 participants · Start Apr 2012 · Primary completion Jan 2014
Drug: Obeticholic acid · For: Primary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea
Sites: London, United Kingdom · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dehydration5
- off label use5
- adenovirus infection4
- anaphylactic shock4
- drug ineffective4
- ear infection4
- gastroenteritis viral4
- herpes zoster disseminated4
- human bocavirus infection4
- lymphopenia4
- multiple organ dysfunction syndrome4
- optic neuritis4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy.
Marks JW, Lan SP, Baum RA, et al. · Ann Intern Med 1984 · Clinical Trial, Randomized Controlled Trial
- Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment.
Marks JW, Baum RA, Hanson RF, et al. · Ann Intern Med 1984 · Clinical Trial, Research Support, U.S. Gov't, P.H.S.
- Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects.
Hanson DS, Duane WC · J Lipid Res 1994 · Clinical Trial, Randomized Controlled Trial
- The present status of agents for dissolving gallstones.
Tangedahl T · Am J Gastroenterol 1985 · Clinical Trial, Comparative Study
- Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety.
Schoenfield LJ, Lachin JM · Ann Intern Med 1981 · Clinical Trial, Randomized Controlled Trial
- Chemical and morphologic characteristics of cholesterol gallstones that failed to dissolve on chenodiol. The National Cooperative Gallstone Study.
Freilich HS, Malet PF, Schwartz JS, et al. · Gastroenterology 1986 · Clinical Trial, Controlled Clinical Trial
Sponsor: Mirum
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.